The following 22 experts are listed against your chosen search criteria of:
Prof Hemant Kocher
Currently, my research is focused on pancreatic cancer. I am investigating the role of cytoskeletal proteins in pancreatic cancer progression, invasion and metastasis. Additional work has included the development of organotypic pancreatic cancer models. I am also developing novel clinical trials and biomarkers inspired by the laboratory results of these studies.
Dr Gunnel Hallden
The research my team and I conduct is focused on the development of novel treatment strategies to target prostate cancers and pancreatic cancers using genetically modified viruses that ideally target, replicate and kill cancer cells (replication-selective oncolytic viruses) but leave normal cells unharmed. The use of viruses in the treatment of cancer is termed virotherapy.
Dr Paul Allen
My research focuses on haematology and leukaemia, drug resistance as well as drug-targeting of leukaemia cells.
Dr Diana Schalke
My research includes the study of genetic changes and alterations in signalling pathways when compared to normal skin. Other interests include Basal cell carcinomas and cutaneous research.
Prof Yongjie Lu
I have set up a research programme of systematic genetic studies of prostate cancer, renal cancer and testicular germ cell tumours (TGCT). The mission of the research team is to identify, using a systematic approach, genomic alterations and genes significance in influencing the development, progression and therapeutic response of male urogenital tumours. I have also started an investigation of genetic and environmental factors associated with key genomic alterations in prostate cancer.
Dr Tatjana Crnogorac-Jurcevic
The focus of my research is pancreatic ductal adenocarcinoma (PDAC), the fifth leading cause of cancer-related death in the UK. This cancer has been deemed a 'silent killer', as it is asymptomatic at an early stage; more then 80% of patients therefore present with already disseminated disease, when curative surgery is not possible any more. The translational research in my laboratory follows two conceptual approaches and aims. The first is to develop a non-invasive test for early detection of PDAC in high-risk population. The second is to develop novel therapies for metastatic disease. This is based on uncovering invasive signatures through molecular analyses of lymph node and liver metastases and perineural invasion. We believe both of these approaches will make a true impact on survival of patients with pancreatic adenocarcinoma.
Prof Jack Cuzick
Our focus is on screening, early detection and disease prevention. Major areas of interest are cancers of the breast, uterine cervix, prostate and colorectum.
Dr Jane Mcgregor
I am part of an active research team examining the development and management of skin cancer in immunosuppressed patients. I also undertake medicolegal work in clinical ethics, clinical negligence and personal injury.
Dr Li Jia
For over 20 years, my main research work focused on overcoming the resistance of leukaemia and lymphoma cells to chemo- or immuno-therapy and the roles of mitochondria and Bcl-2 family proteins in apoptotic cell death. Currently, my studies focus on the impact of the inflammatory microenvironment and autophagy on the development and survival mechanism of chronic lymphocytic leukaemia and B cell lymphoma.
Prof Marta Korbonits
I am interested in clinical and research issues regarding pituitary adenomas, related genetic conditions and established and developing treatments. Other areas of interest include growth hormone regulation, ghrelin, cannabinoids and metabolic regulation.
Prof Frances Balkwill
I am interested in cancer development and spread, as well as ovarian cancer. I also conduct research on HIV/Aids and specialise in science communication and engagement with children.
Prof John Marshall
Tumour spread and metastasis; regulation of these by cell adhesion receptors and their associated molecules; molecular and cell biology.
Prof Rino Cerio
I am the UK's only expert on dermatopathology. Other areas of expertise include immunofluorescence, skin cancer, psoriasis and immunodermatosis.
Prof Janet Jones
The role of the microenvironment in the control of breast tumour behaviour, using complex culture model systems with primary cells, to manipulate the environment and measure funtional effects.
Prof Kairbaan Hodivala-Dilke
Prof Eric Parkinson
I am an expert in cellular ageing and how this breaks down in cancer, especially mouth and throat cancer.
Prof Jude Fitzgibbon
My main area of research is the molecular basis of haematologic malignancies (leukaemia and lymphoma).
Dr Alan Cruchley
My research activity has built on my work for my PhD and has been primarily concerned with the defensive and protective capacity of oral mucosa. I have published on the role of the permeability barrier in oral disease, the role of saliva derived growth factors in mucosal protection and drug delivery across the oral mucosa. I have developed an in vitro assay to study the role of the mucosal barrier in mucosal health and disease. My work with the model has attracted significant industrial funding, exploring the effect of oral health products and components on the oral mucosa and investigating the mechanisms underlying the responses of the epithelium. I am currently using this model to investigate mucosal barrier homeostasis, the pathogenesis of oral submucous fibrosis and oral cancer; and the role of the barrier in the response of the mucosa to host commensal and pathogenic organisms.
Prof Nicholas Lemoine
Research interests include cancer, specifically the molecular pathology of solid malignancies, gene transcription biology, cell survival signalling, molecular therapeutics including gene therapy, and vaccine approaches.
Prof John Gribben
My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
Prof Stephen Duffy
My research is aimed at evaluating cancer screening programmes, and devising innovations to these which will improve their effect on death from cancer, enhance their acceptability to the public and minimise side effects of screening, such as false positive rates.
Dr Richard Grose
Mouse and cell culture models of cancer and wound healing; Growth factor signaling in development, repair and cancer.